Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

N Engl J Med. 2010 Mar 4;362(9):774-7. doi: 10.1056/NEJMp1001578. Epub 2010 Feb 17.
No abstract available

MeSH terms

  • Animals
  • Biomarkers / blood
  • Calcitonin / blood
  • Cardiovascular Diseases
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Approval*
  • Drug Therapy, Combination
  • Glucagon-Like Peptide 1 / adverse effects
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Glucagon-Like Peptide 1 / therapeutic use
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use
  • Liraglutide
  • Pancreatitis / chemically induced
  • Risk Factors
  • Rodentia
  • Thyroid Neoplasms / chemically induced*
  • United States
  • United States Food and Drug Administration

Substances

  • Biomarkers
  • Hypoglycemic Agents
  • Liraglutide
  • Glucagon-Like Peptide 1
  • Calcitonin